4 Results for "

T cell subpopulations

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "T cell subpopulations" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P99048
CAS No.: 2072873-06-2
Synonyms: IBI308

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
loading...
    loading...
Cat. No.: HY-108161
CAS No.: 86187-86-2
Target:  

Interleukin Related

Research Areas:  

Others

LF 1695 is an immunomodulator. LF 1695 enhances the proliferative response of T cells by increasing the production of IL2 (interleukin-2) or the expression of the IL2 receptor. LF 1695 also increases CONA-induced inhibitory activity in human lymphocytes. LF 1695 can be used to study the proliferative and inhibitory activity of T cell subpopulations, as well as their role in immune regulation .
loading...
    loading...
Cat. No.: HY-P99048A
Synonyms: IBI308 (Anti-PD-1)

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
loading...
    loading...
Cat. No.: HY-186305
CAS No.: 3078747-38-0
Target:  

Liposome

Research Areas:  

Others

VL-422 derivative is an ionizable lipid component of targeted lipid nanoparticles. VL-422 derivative formulated with a helper lipid, cholesterol, and a PEGylated lipid forms lipid nanoparticles (LNPs). VL-422 derivative can be used for in vivo or ex vivo delivery of agents to immune cells .
loading...
    loading...